LAMB1, short for laminin subunit beta 1, is a principal component of laminins, a family of large cross-shaped molecules that form a core part of the basement membrane, the specialized extracellular matrix layer that underlies and supports epithelial tissues. In healthy organs, laminins provide structural scaffolding, anchor cells in place, and transmit signals that regulate differentiation, adhesion, and migration. But over the past decade, cancer biologists have increasingly recognized that this same scaffold can be hijacked. Elevated LAMB1 levels have been linked to poor outcomes in gastric cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, and a 2025 comprehensive review in the Journal of Translational Medicine catalogued the growing evidence that laminins actively shape cancer pathobiology rather than merely serving as passive architectural supports.

What remained unclear until now was LAMB1’s role in esophageal squamous cell carcinoma, a tumor type that arises from the flat epithelial cells lining the esophagus and that accounts for the majority of esophageal cancer cases worldwide. According to GLOBOCAN 2020 estimates cited by the researchers, the global burden of esophageal squamous cell carcinoma and esophageal adenocarcinoma remains substantial, with projections to 2040 indicating continued pressure on health systems, particularly in regions where the squamous form dominates. Despite advances in surgery, chemoradiotherapy, and, more recently, perioperative immunotherapy, five-year survival for many patients diagnosed with this disease remains discouraging, motivating a search for molecular markers that could guide earlier detection and more precise treatment.

To find such markers, the team began with bioinformatic screening of datasets from The Cancer Genome Atlas, cross-referencing tumor expression data with curated gene sets related to the extracellular matrix. Their computational sweep identified LAMB1 as a candidate gene associated with prognosis in esophageal squamous cell carcinoma. That prediction was then tested experimentally. Using quantitative polymerase chain reaction to measure messenger RNA, Western blotting to quantify protein, and immunohistochemistry to visualize where LAMB1 accumulates within tissue sections, the researchers demonstrated that LAMB1 expression was consistently elevated in esophageal squamous cell carcinoma tissues and in cell lines derived from the disease, compared with normal counterparts.

Expression, however, is only half the story; the critical question is whether LAMB1 actively drives malignancy or merely accompanies it. To answer this, the team performed gain- and loss-of-function experiments. When they forced LAMB1 overexpression in esophageal cancer cells, the cells became more aggressive: they proliferated faster, migrated more readily across experimental surfaces, and invaded more deeply through matrix-coated membranes in the laboratory assays. Conversely, when the researchers silenced LAMB1 using knockdown techniques, these malignant phenotypes were suppressed, with proliferation, migration, and invasion all dropping. The symmetry of the results, directionally consistent whether LAMB1 was added or removed, strengthens the causal interpretation that this matrix protein is not a bystander but an active promoter of tumor behavior.

The mechanistic heart of the study lies in the JAK2/STAT3 signaling cascade, a canonical communication channel inside cells. Janus kinases, or JAKs, are enzymes that attach phosphate groups to proteins, and when the JAK2 kinase is activated, it phosphorylates the STAT3 transcription factor. Phosphorylated STAT3 then travels to the nucleus, where it switches on genes that promote cell survival, cell-cycle progression, angiogenesis, metastasis, and resistance to chemotherapy. In esophageal squamous cell carcinoma specifically, prior research has shown that activated STAT3 can reduce patient survival by upregulating vascular endothelial growth factor and cyclin D1, and other studies have linked pathway activation to epithelial-mesenchymal transition, the process by which epithelial cancer cells acquire the motile, invasive characteristics needed to metastasize.

The new experiments connected LAMB1 to this cascade with unusual clarity. The researchers found that LAMB1 activates JAK2/STAT3 signaling by enhancing protein phosphorylation, effectively turning up the volume on the pathway. The proof of causation came from two independent interventions. First, the team treated the cells with ruxolitinib, a JAK1/2 inhibitor already approved for clinical use in certain blood disorders, and the drug efficiently abrogated the malignant phenotypes that LAMB1 had driven. Second, they silenced STAT3 directly with knockdown technology and observed the same reversal. In both cases, blocking the pathway erased the proliferative, migratory, and invasive advantages conferred by LAMB1, establishing that LAMB1 acts upstream and depends on JAK2/STAT3 to exert its tumor-promoting effects.

To confirm that the mechanism operates in living organisms and not only in culture dishes, the researchers turned to xenograft experiments, in which human cancer cells are implanted into laboratory animals under institutional ethical oversight. Tumors engineered with LAMB1 knockdown grew significantly less than controls, and molecular analysis of the resulting tumor tissue showed reduced activation of the JAK2/STAT3 pathway, mirroring the in vitro findings. The study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University and the institution’s animal care committee, and informed consent was obtained from all human participants, providing the governance framework that lends the results their clinical credibility.

The translational implications are twofold. As a biomarker, LAMB1’s elevated expression and its association with prognosis suggest that measuring it in tumor biopsies could help stratify patients, potentially identifying those with more aggressive disease who might benefit from intensified treatment or closer surveillance. As a therapeutic target, the ruxolitinib result is particularly intriguing because JAK inhibitors are already in clinical use, and the broader JAK2/STAT3 axis has attracted substantial pharmaceutical attention, with structural analysis and structure-activity relationship investigations fueling the development of pathway-targeting compounds. The study hints that esophageal cancer patients whose tumors are driven by LAMB1 might, in principle, respond to agents that interrupt this signaling route, although the researchers caution that much work remains before such a strategy could be tested in patients with this solid tumor.

There are also important caveats and open questions. The study did not receive external funding, and the authors declare no competing interests, but single-pathway mechanisms rarely explain a cancer’s full behavior, and LAMB1 has been implicated in other signaling routes, including the Hippo-YAP1 pathway in hepatocellular carcinoma and ERK/c-Jun signaling in gastric cancer, raising the possibility of parallel or interacting mechanisms in the esophagus as well. Moreover, how LAMB1 physically engages JAK2, whether through integrin receptors at the cell surface, mechanotransduction from matrix stiffness, or another route, remains to be dissected. Data supporting the study are available from the corresponding author upon reasonable request, and the corresponding author, Ziqiang Tian, led the supervision of the project. Still, by tracing a line from an extracellular scaffold protein through a druggable kinase cascade to the malignant behavior of one of the world’s most lethal cancers, the study adds a compelling new link in the chain that connects tumor architecture to tumor aggression, and it hands researchers a concrete new lead in a disease that badly needs one.

Subject of Research: The role of the extracellular matrix protein LAMB1 and the JAK2/STAT3 signaling pathway in the progression of esophageal squamous cell carcinoma

Article Title: LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling

Article References: Zhang, M., Liu, Z., Lv, H., Li, Z., Zhao, L., & Tian, Z. (2026). LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling. Molecular Biology Reports, 53(1), Article 1721. https://doi.org/10.1007/s11033-026-12853-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12853-0

Keywords: LAMB1, esophageal squamous cell carcinoma, JAK2/STAT3 signaling, extracellular matrix, laminin, ruxolitinib, STAT3 phosphorylation, xenograft, biomarker, cancer progression, phosphorylation, Molecular Biology Reports

Beta-thalassemia major is one of the most common inherited hemoglobin disorders in the world, concentrated in the Mediterranean basin, the Middle East, and Southeast Asia. The disease stems from defective synthesis of the beta-globin chain of hemoglobin, which produces ineffective red blood cell formation, chronic anemia, and a lifelong dependence on regular transfusions to keep hemoglobin levels adequate for normal growth. Although chronic transfusion combined with iron chelation therapy has dramatically improved survival, the inevitable iron overload continues to damage the heart, liver, and endocrine organs over time. Allogeneic hematopoietic stem cell transplantation remains the only established curative option, replacing the patient’s defective blood-forming system with donor cells that produce normal adult hemoglobin.

The boy in this report was diagnosed at three months of age, when hemoglobin electrophoresis revealed 82 percent fetal hemoglobin and only 15 percent HbA1. He received monthly transfusions with iron chelation until age four, when he was evaluated for transplantation. Pre-transplant workup included viral, cardiac, pulmonary, dental, ENT, and psychological assessments, along with whole-body computed tomography that showed only increased hepatic density. A liver biopsy demonstrated Grade I parenchymal iron overload without portal fibrosis. Under the Pesaro classification, used to stratify thalassemia patients by transplant risk, he was categorized as Class I, the most favorable group. His fully matched sibling donor provided peripheral blood stem cells totaling 11 million CD34-positive cells per kilogram and 580 million CD3-positive cells per kilogram.

Conditioning followed the EBMT protocol, combining busulfan at 4.4 milligrams per kilogram daily for four days, cyclophosphamide at 50 milligrams per kilogram daily for four days, and anti-lymphocyte globulin for two days. Prophylaxis against graft-versus-host disease consisted of methotrexate with leucovorin rescue plus cyclosporine A. Engraftment came quickly, with platelets recovering on day 13 and neutrophils on day 15, and day-30 chimerism analysis showed 99.2 percent donor cells. Then, on day 23, the child developed fatigue, progressive jaundice, and a liver enlarged four centimeters below the costal margin, with no rash whatsoever. Laboratory testing revealed the signature of severe cholestatic injury: alanine aminotransferase of 250 units per liter, gamma-glutamyl transferase of 936, and bilirubin climbing to at least 20 milligrams per deciliter. Screening for viral hepatitis and cytomegalovirus was negative, and the team diagnosed Grade III acute hepatic-predominant graft-versus-host disease with concurrent Grade II gastrointestinal involvement.

The absence of skin findings forced the clinicians into a careful differential diagnosis, because early post-transplant liver failure has several dangerous mimics. Sinusoidal obstruction syndrome, also called veno-occlusive disease, typically presents with unexplained weight gain, fluid retention, ascites, abdominal distension, hepatomegaly, and thrombocytopenia under the pediatric EBMT criteria. This boy showed none of those features: his weight stayed locked between 15.3 and 15.5 kilograms throughout the episode, he had no ascites or distension, and his platelet count remained normal. Doppler ultrasonography showed normal hepatic echogenicity with only mild hepatic vein dilatation and a mild rise in portal venous pressure, findings the team interpreted cautiously within the overall clinical picture rather than as diagnostic proof in either direction.

Transplantation-associated thrombotic microangiopathy was the other major consideration. The international consensus definition rests on a combination of anemia, thrombocytopenia, elevated lactate dehydrogenase, schistocytes on the blood smear, hypertension, elevated soluble C5b-9, and proteinuria. In this patient, platelets stayed within normal limits, LDH was normal at 250 units per liter, no schistocytes were seen, blood pressure remained normal, urinalysis showed no proteinuria, and renal function was preserved with a creatinine of 0.6 milligrams per deciliter at admission. The combination of marked cholestatic dysfunction, hepatomegaly, concurrent gastrointestinal graft-versus-host disease, exclusion of viral causes, and, ultimately, a clear response to graft-versus-host-directed therapy made hepatic-predominant acute graft-versus-host disease the most defensible diagnosis, although the authors are careful to note it remained clinically supported rather than histologically confirmed, since no liver biopsy was performed during the acute episode.

Treatment began with prednisolone at 2 milligrams per kilogram daily, cyclosporine at 5 milligrams per kilogram daily, and azathioprine, supplemented by ursodeoxycholic acid, silymarin, cholestyramine, and intravenous acetylcysteine to support the injured liver. When this regimen produced only limited clinical and biochemical response, with jaundice and cholestasis persisting, the team escalated. Mycophenolate mofetil was added at 50 milligrams per kilogram daily, ruxolitinib at 5 milligrams daily, and rituximab at 375 milligrams per square meter weekly. Ruxolitinib, a selective inhibitor of JAK1 and JAK2, blocks the inflammatory signaling cascades that drive graft-versus-host disease and has become a standard option for steroid-refractory disease in adults, with growing pediatric evidence behind it. Within three weeks of escalation, the jaundice and hepatomegaly regressed markedly, liver enzymes improved substantially, and the gastrointestinal symptoms resolved.

The follow-up data over a full year underscore how complete the recovery was. Donor chimerism remained stable at 100 percent at three months, 99 percent at six months, 99.4 percent at nine months, and 99 percent at twelve months. Liver function normalized dramatically, with alanine aminotransferase falling from 250 to 35 units per liter, aspartate aminotransferase from 200 to 32, and gamma-glutamyl transferase from 936 to 45, while bilirubin returned to normal and albumin held steady at about 3.7 grams per deciliter. Hemoglobin electrophoresis at nine and twelve months showed sustained donor-type hemoglobin production, with HbA1 at 97 percent and HbA2 at 2.9 percent. The boy remained transfusion-independent throughout, immunosuppression was gradually tapered and discontinued, and he resumed normal daily activities with no evidence of thrombotic microangiopathy at any point.

The case adds to a still-limited pediatric experience with severe hepatic-predominant acute graft-versus-host disease, and the authors place their result in the context of the ruxolitinib literature. An early retrospective pediatric series by Khandelwal and colleagues reported an overall response rate of 45 percent at four weeks in children with steroid-refractory disease, while the prospective REACH4 study reported an overall response rate of 84.4 percent at day 28 and a durable response rate of 66.7 percent at day 56. The authors caution, however, that because multiple immunosuppressive agents were given concurrently, the contribution of any single drug, whether ruxolitinib or rituximab, cannot be disentangled from a single case. They also acknowledge that biomarkers such as soluble C5b-9 and haptoglobin were unavailable, so competing diagnoses cannot be excluded with absolute certainty.

Even with those limitations, the clinical lessons are concrete. Severe hepatic acute graft-versus-host disease can strike without any cutaneous manifestation and belongs in the differential of significant cholestatic liver dysfunction after transplantation. Progressive hepatic failure in the early post-transplant period demands systematic evaluation for sinusoidal obstruction syndrome and thrombotic microangiopathy, with longitudinal tracking of weight, fluid status, platelet count, LDH, renal function, blood pressure, peripheral smear, and urinary protein providing the discriminating evidence. And in settings where advanced diagnostics are scarce, the case suggests that early recognition paired with timely therapeutic escalation and close multidisciplinary monitoring can still deliver excellent outcomes, a message with real weight for the many transplant programs operating in resource-limited regions where thalassemia imposes its heaviest burden.

Subject of Research: Management of severe hepatic-predominant acute graft-versus-host disease after allogeneic stem cell transplantation in a child with beta-thalassemia major

Article Title: Successful Management of Severe Hepatic Acute Graft‐Versus‐Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β‐Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation

Article References: Alhiraki, H., Fares, A. A., & Kheder, M. (2026). Successful Management of Severe Hepatic Acute Graft‐Versus‐Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β‐Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation. Clinical Case Reports, 14(10), Article e73623. https://doi.org/10.1002/ccr3.73623

Image Credits: AI Generated

DOI: 10.1002/ccr3.73623

Keywords: graft-versus-host disease, beta-thalassemia major, hematopoietic stem cell transplantation, ruxolitinib, rituximab, cholestatic liver dysfunction, pediatric transplantation, sinusoidal obstruction syndrome, thrombotic microangiopathy, donor chimerism, immunosuppressive therapy, case report

Polycythemia vera is a chronic myeloproliferative neoplasm in which the bone marrow produces too many red blood cells, driven in the vast majority of cases by the acquired JAK2 V617F mutation that keeps the JAK-STAT signaling pathway permanently switched on. Patients face elevated risks of thrombosis and, in high-risk disease, progression toward myelofibrosis or acute leukemia. Standard management has long relied on phlebotomy and cytoreductive agents such as hydroxyurea to keep blood counts down. Ruxolitinib, by contrast, is an oral targeted inhibitor of the Janus kinases JAK1 and JAK2, and it does double duty: it reduces the abnormal cell production driven by mutant JAK2 signaling while also damping down the inflammatory cytokine storm that these disorders generate, including pro-inflammatory mediators such as interleukin-6 and tumor necrosis factor. It is precisely this dual identity, cytoreductive and immunosuppressive at once, that made it the logical therapeutic experiment in this case.

The patient’s clinical course began conventionally enough. He was diagnosed with high-risk polycythemia vera and achieved hematologic complete remission on hydroxyurea, meaning his blood counts returned to and remained within normal ranges. More than five years later, however, he developed histiocytoid Sweet syndrome, an uncommon variant of a condition first described in 1964 by Robert Sweet as acute febrile neutrophilic dermatosis. Classic Sweet syndrome presents with fever, raised painful plaques and nodules, and skin biopsies showing dense infiltrates of mature neutrophils without evidence of infection. In the histiocytoid variant, the infiltrating cells are immature myeloid cells that resemble histiocytes under the microscope, expressing myeloperoxidase and often posing a genuine diagnostic challenge because they can mimic leukemia cutis, the skin infiltration of leukemic cells. Distinguishing the two matters enormously, because one is an inflammatory paraneoplastic phenomenon and the other signals overt malignant spread.

Sweet syndrome is classified into three broad categories: idiopathic or classic, drug-induced, and malignancy-associated. The malignancy-associated form most often accompanies hematologic cancers, including acute myeloid leukemia, myelodysplastic syndromes and the myeloproliferative neoplasms to which polycythemia vera belongs. The prevailing hypothesis is that the underlying clonal disorder somehow triggers a reactive, systemic inflammatory process in the skin, possibly through aberrant cytokine production by the abnormal hematopoietic cells themselves. This framing has a direct therapeutic consequence: in secondary or reactive Sweet syndrome, treating the underlying disease is considered a mainstay of therapy, not merely an adjunct. Yet the Swiss case pushes that principle into uncomfortable territory, because the underlying disease was, by every standard hematologic measure, already controlled.

Initial treatment of the skin eruption followed established practice. Corticosteroids produced a temporary complete resolution of the Sweet syndrome, which is the expected first-line response, since systemic steroids remain the most reliably effective therapy for this condition. The trouble came with tapering. At the first relapse, the eruption returned promptly whenever the prednisone dose was reduced below 10 milligrams daily, a pattern familiar to any clinician who has managed steroid-dependent inflammatory disease and a recipe for long-term steroid toxicity, including osteoporosis, diabetes, infection risk and adrenal suppression. The team then tried steroid-sparing alternatives. Both colchicine, a microtubule-disrupting agent widely used in neutrophilic dermatoses and autoinflammatory syndromes, and dapsone, an antibiotic with potent anti-neutrophilic properties, failed. The malignancy-associated histiocytoid Sweet syndrome proved refractory to both agents, leaving the patient dependent on corticosteroids with no conventional exit strategy.

At this point the treatment team made a decision grounded in pharmacological reasoning rather than precedent. Given ruxolitinib’s potent anti-inflammatory and immunosuppressive properties, and its established role in the treatment of polycythemia vera itself, they switched the patient’s cytoreductive therapy from hydroxyurea to ruxolitinib, aiming to treat both conditions with a single drug. The rationale rests on the biology of the JAK-STAT pathway. JAK1 and JAK2 transduce signals from a range of cytokine and growth factor receptors, and ruxolitinib’s inhibition of this axis suppresses not only the neoplastic clone in myeloproliferative neoplasms but also the downstream inflammatory signaling that is thought to drive paraneoplastic phenomena. In myelofibrosis, ruxolitinib is well known for reducing splenomegaly and, notably, for relieving constitutional symptoms such as night sweats and pruritus that are themselves cytokine-mediated, an effect that hinted at its broader immunomodulatory reach.

The gamble worked. Within six weeks of initiating ruxolitinib, the histiocytoid Sweet syndrome resolved completely, and the resolution proved durable: the patient maintained remission of the skin disease even after corticosteroids were discontinued entirely, while his polycythemia vera remained in hematologic remission throughout. The case therefore demonstrates two things simultaneously. First, it confirms that ruxolitinib can control steroid-refractory, steroid-sparing-agent-resistant Sweet syndrome in the setting of a myeloproliferative neoplasm. Second, and more conceptually important, it shows that clonal disease driving a paraneoplastic inflammatory syndrome can persist at a level undetectable by conventional hematologic monitoring. Hematologic complete remission, in other words, does not guarantee absence of the biological activity that fuels malignancy-associated Sweet syndrome, and the skin can serve as a sensitive readout of that residual activity.

The authors draw a practical conclusion from this that they state explicitly in their report: in patients with hematological malignancies and associated Sweet syndrome, modification of the underlying disease treatment may be considered even in the presence of hematologic complete remission, particularly when conventional Sweet syndrome therapies fail. This is a meaningful shift in emphasis. The traditional algorithm for malignancy-associated Sweet syndrome treats the skin disease and the cancer on parallel tracks, escalating skin-directed therapy with steroids, then steroid-sparing agents such as colchicine, dapsone, potassium iodide or cyclosporine, while cancer therapy proceeds independently. The Swiss case suggests that when the skin disease is refractory to that first tier, the smarter move may be to change the hematologic therapy itself, choosing an agent whose anti-inflammatory profile can reach the reactive process that conventional immunosuppressants cannot fully control.

There are, of course, the usual caveats that attach to any single-patient report. A case report establishes feasibility and biological plausibility, not efficacy; it cannot rule out spontaneous remission, and it cannot define the optimal dose, timing or patient selection for ruxolitinib in this setting. Ruxolitinib carries its own risk profile, including cytopenias and increased susceptibility to herpes zoster and other infections, which is why it is not a casual substitute for hydroxyurea in every patient. Nor is it yet clear whether the same strategy would work in Sweet syndrome associated with other hematologic malignancies, such as acute myeloid leukemia or myelodysplastic syndromes, where the cytokine milieu and clonal biology differ. What the case does establish is a testable hypothesis and a documented precedent, published with the patient’s written informed consent and conducted in accordance with the Declaration of Helsinki, that other clinicians can now build on.

Perhaps the most enduring message of the report is procedural rather than pharmacological: the authors emphasize that close collaboration between hematologists and dermatologists is essential in these cases. Histiocytoid Sweet syndrome sits precisely at the boundary between the two specialties, requiring dermatopathological expertise to distinguish it from leukemia cutis and hematological expertise to interpret what the skin eruption says about the state of the underlying clone. As targeted agents with immunomodulatory effects proliferate across oncology, the boundary cases are likely to multiply, and this Swiss patient’s six-week cure suggests that the most effective therapy for a paraneoplastic skin disease may sometimes be found not in the dermatology formulary but in the hematology one.

Subject of Research: Ruxolitinib treatment of histiocytoid Sweet syndrome associated with polycythemia vera

Article Title: Ruxolitinib-responsive histiocytoid sweet syndrome in a patient with polycythemia vera in hematologic remission – a case report

Article References: Rüfer, A., Senn, M., Kündig, T., & Zeerleder, S. (2026). Ruxolitinib-responsive histiocytoid sweet syndrome in a patient with polycythemia vera in hematologic remission – a case report. Annals of Hematology. https://doi.org/10.1007/s00277-026-07291-8

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07291-8

Keywords: polycythemia vera, Sweet syndrome, histiocytoid Sweet syndrome, ruxolitinib, JAK inhibitors, hydroxyurea, corticosteroids, colchicine, dapsone, paraneoplastic dermatosis, myeloproliferative neoplasm, case report

The new analysis, published in Annals of Hematology by a team led by researchers at the Children’s Hospital of Chongqing Medical University, pooled data from 83 studies covering 542 patients treated with ruxolitinib-based regimens. Because no randomized controlled trials have ever evaluated ruxolitinib in hemophagocytic lymphohistiocytosis, the investigators conducted a systematic review and single-arm meta-analysis, registered prospectively with PROSPERO under identifier CRD42025639580. Their headline finding: the pooled overall response rate was 87.2 percent, with a 95 percent confidence interval of 80.8 to 92.7 percent and moderate statistical heterogeneity. When the authors split the results by disease subtype, a clear divide emerged. Patients with primary, or familial, hemophagocytic lymphohistiocytosis—a genetic disorder of immune regulation—achieved a response rate of 100 percent in the pooled data, compared with 82.4 percent in secondary forms triggered by infections, malignancies, or autoimmune disease, a difference that was statistically significant.

Survival figures told a similar story in the short term. The pooled overall survival rate was 91.6 percent at two months, falling to 81.6 percent at six months and 73.9 percent at one year, reflecting the relentless attrition that characterizes this syndrome even under modern therapy. Again, the primary form showed an advantage: 100 percent survival at two months versus 87.7 percent in secondary disease. The authors emphasize that these estimates remained robust in sensitivity analyses that excluded individual case reports, which are often criticized for publication bias since clinicians tend to publish successes rather than failures. Of the 83 included studies, 27 were single-arm trials or cohort studies while 56 were case reports or series, making the exclusion analysis a critical test of whether the headline numbers were propped up by anecdote. They were not.

To understand why these results matter, it helps to understand what ruxolitinib actually does. The drug is an inhibitor of Janus kinases 1 and 2, enzymes that sit at the receiving end of signaling pathways used by many inflammatory cytokines, including interferon-gamma and interleukins that drive T-cell and macrophage activation. In hemophagocytic lymphohistiocytosis, hyperactivated CD8-positive T cells and macrophages flood the body with these cytokines, causing fever, spleen enlargement, falling blood counts, liver injury, and, in the worst cases, multi-organ failure. By dampening cytokine signaling at the intracellular level, ruxolitinib acts upstream of the cellular destruction, calming the storm rather than simply suppressing the immune system wholesale with cytotoxic chemotherapy. This mechanism is why hematologists began experimenting with it off-label in the most desperate cases—patients failing standard etoposide-based regimens, for instance, or infants with genetic disease awaiting stem cell transplantation.

The distinction between primary and secondary disease is central to the new findings. Primary hemophagocytic lymphohistiocytosis arises from inherited defects in genes governing the cytotoxic machinery of natural killer cells and CD8 T cells, such as perforin pathways, and historically it was almost always fatal in infancy without hematopoietic stem cell transplantation. Secondary, or acquired, forms erupt on top of infections like Epstein-Barr virus, malignancies, or autoimmune conditions, and their biology is more heterogeneous, reflecting diverse underlying triggers. The higher pooled response rate in the primary form may seem counterintuitive at first—genetic disease might be expected to be harder to treat—but it fits with the drug’s mechanism. In primary disease, the cytokine loop is driven by a relatively uniform defect in cytotoxic function, and blocking the downstream signaling amplifiers may interrupt the feedback circuit very effectively. Secondary disease, by contrast, is entangled with the underlying trigger: a lymphoma continues to grow, a viral infection persists, and ruxolitinib alone cannot remove the source of the inflammation. The authors also observed more frequent pancreatic injury and severe hematological toxicity in the primary group, hinting that treatment intensity or disease biology differs between the subtypes in ways that deserve dedicated study.

Safety data from the synthesis add important nuance for clinicians weighing the drug at the bedside. The most frequent adverse events across the pooled population were infections at 9.3 percent, neutropenia at 7.5 percent, and hepatic dysfunction at 7.0 percent. These figures are notable because they are modest for a drug used in critically ill, profoundly immunosuppressed patients, but they are not trivial. Ruxolitinib’s immunosuppressive mechanism raises a theoretical concern about reactivation of latent infections, and cytomegalovirus reactivation in particular has been reported in clinical experience with the drug. The analysis does not settle that question definitively, and the authors are candid that rare disease research carries inherent limitations: no randomized comparisons, heterogeneous dosing and combination regimens, variable definitions of response across studies, and follow-up that is often short in a syndrome where patients may die quickly or be rescued by transplantation.

Those caveats frame the study’s real contribution. By aggregating every available strand of evidence—trials, cohorts, and hundreds of individually reported cases—the analysis provides the first quantitative benchmark for what clinicians can realistically expect from ruxolitinib-based therapy in each subtype. An 87 percent pooled response rate across the spectrum, with survival above 90 percent at two months, is a signal strong enough to inform practice today and to shape the design of the trials that must follow. The subgroup difference is arguably the most actionable finding: it suggests that in secondary hemophagocytic lymphohistiocytosis, ruxolitinib should probably be positioned as part of a strategy that simultaneously attacks the underlying trigger, whether that is antiviral therapy, chemotherapy for lymphoma, or immunosuppression for autoimmune disease, rather than as monotherapy expected to carry the patient alone.

The authors, led by Zirui Ding with senior authorship from Xi Yang, Xiaodong Zhao, and Ximing Xu among a team spanning Chongqing and Tokyo, including Hirokazu Kanegane of Institute of Science Tokyo, write that their findings provide critical guidance for clinical practice and future trial design despite the limitations inherent in studying a rare disease. The research was supported by grants from Chongqing municipal health and science funding programs, and the work reflects the growing capacity of pediatric immunology and hematology centers in China to mount large evidence syntheses in ultra-rare conditions where no single institution sees enough patients to study them alone.

For the rare disease community, the study lands at a moment of genuine momentum. Ruxolitinib has already been tested in randomized trials for graft-versus-host disease and is approved for several myeloproliferative neoplasms, giving physicians extensive familiarity with its dosing and toxicity profile. The new meta-analysis extends that familiarity into one of hematology’s most lethal emergencies, and its subtype-specific numbers give trial designers a clear benchmark against which future randomized studies of ruxolitinib in primary and secondary disease can be powered. What remains to be shown is whether the dramatic early responses translate into durable cures, particularly for patients with genetic disease who ultimately need stem cell transplantation, and whether the drug’s benefit in secondary forms depends critically on how aggressively the underlying trigger is treated alongside it. Those answers will require the very trials this synthesis is designed to enable.

Subject of Research: Efficacy and safety of the JAK1/JAK2 inhibitor ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis

Article Title: Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

Article References: Ding, Z., Zhang, Z., Dou, Y., Jia, Y., An, Y., Tang, X., Kanegane, H., Xu, X., Zhao, X., & Yang, X. (2026). Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07274-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07274-9

Keywords: hemophagocytic lymphohistiocytosis, ruxolitinib, JAK1/JAK2 inhibitor, meta-analysis, primary HLH, secondary HLH, overall response rate, overall survival, adverse events, rare disease, immunotherapy, hematology